Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELAHERE vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ELAHERE (mirvetuximab soravtansine) is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). It consists of a humanized anti-FRα antibody conjugated to the maytansinoid DM4, a microtubule inhibitor. Upon binding to FRα on tumor cells, the ADC is internalized and releases DM4, which binds to tubulin and disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens (FDA approved indication)
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
6 mg/kg adjusted ideal body weight intravenously every 3 weeks until disease progression or unacceptable toxicity.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal half-life approximately 6.2 days (range 3.7-9.5 days) after IV administration; supports every-3-week dosing interval.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
The DM4 component is primarily metabolized by CYP3A4 and, to a lesser extent, by CYP3A5 and CYP2D6. The antibody component undergoes catabolism via proteolytic degradation.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Fecal (approximately 80%) as unchanged drug; renal (approximately 8%) as unchanged drug and metabolites.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Approximately 95% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
82–88% bound to plasma proteins (primarily albumin).
Mean Vd approximately 0.27 L/kg (range 0.14-0.54 L/kg), indicating distribution primarily in plasma and extracellular fluid.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Intravenous only; oral bioavailability not applicable (0% by oral route).
Oral: 65–80% (median 73%)
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min).
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C).
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Safety and efficacy not established in pediatric patients.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustment recommended. Elderly patients (≥65 years) experienced higher rates of serious adverse reactions; monitor closely.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
ELAHERE is not approved for use in patients with platinum-sensitive disease due to increased toxicity and mortality observed in a clinical trial. No other black box warnings.
None
Ocular toxicity: Corneal toxicity, including keratopathy, blurred vision, dry eyes, and photophobia. Requires ophthalmic monitoring and management with prophylactic corticosteroid eye drops.,Pneumonitis/Interstitial lung disease (ILD): Monitor for cough, dyspnea, or hypoxia; withhold or discontinue if severe.,Peripheral neuropathy: Monitor for sensory or motor neuropathy; dose modify as needed.,Embryo-fetal toxicity: Can cause fetal harm; advise patients of reproductive potential to use effective contraception.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Known severe hypersensitivity to mirvetuximab soravtansine or any of its components,Use in patients with platinum-sensitive disease as safety and efficacy not established and increased risk of serious adverse events
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Avoid grapefruit and grapefruit juice during treatment as they may increase mirvetuximab soravtansine exposure. No other significant food interactions reported.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Based on its mechanism of action (folate receptor alpha-directed antibody-drug conjugate containing maytansinoid DM4, a microtubule inhibitor), ELAHERE is expected to cause embryofetal toxicity and teratogenicity. Malformations and developmental abnormalities are likely if administered during the first trimester. Second and third trimester exposure may result in fetal growth restriction, oligohydramnios, and organ dysfunction due to anti-mitotic effects. There are no adequate human data; animal studies have not been conducted.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
No data on presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions (e.g., myelosuppression, neurotoxicity) in nursing infants, advise not to breastfeed during treatment and for at least 1 week after the last dose. M/P ratio unknown.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No recommended dose adjustments in pregnancy due to lack of pharmacokinetic data. Pregnancy is a contraindication due to embryofetal toxicity. If treatment is necessary, exposure-adjusted dosing has not been studied; consider alternative therapies.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
ELAHERE (mirvetuximab soravtansine) is an antibody-drug conjugate targeting folate receptor alpha (FRα). Administer premedications to reduce infusion reactions. Monitor for ocular toxicity including blurred vision, keratopathy, and dry eye; refer to ophthalmology if symptoms occur. Assess for interstitial lung disease. Use with caution in patients with hepatic impairment due to potential for hepatotoxicity. Contraception required during treatment and for 7 months after last dose.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
This drug targets a protein called folate receptor alpha found on some cancer cells.,You will receive this medication as an intravenous (IV) infusion every 3 weeks.,Common side effects include fatigue, nausea, diarrhea, and blurred vision.,Report any vision changes, shortness of breath, or yellowing of the skin/eyes immediately.,Use effective contraception during treatment and for 7 months after the last dose.,Do not breastfeed during treatment and for 1 month after the last dose.,Stay hydrated and eat small, frequent meals to manage nausea and diarrhea.,Avoid grapefruit and grapefruit juice as it may interact with this medication.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELAHERE vs AGRYLIN, answered by our medical review team.
ELAHERE is a Antineoplastic Agent that works by ELAHERE (mirvetuximab soravtansine) is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). It consists of a humanized anti-FRα antibody conjugated to the maytansinoid DM4, a microtubule inhibitor. Upon binding to FRα on tumor cells, the ADC is internalized and releases DM4, which binds to tubulin and disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELAHERE and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELAHERE is: 6 mg/kg adjusted ideal body weight intravenously every 3 weeks until disease progression or unacceptable toxicity.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELAHERE and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELAHERE is classified as Category C. Based on its mechanism of action (folate receptor alpha-directed antibody-drug conjugate containing maytansinoid DM4, a microtubule inhibitor), ELAHERE is expected to cause embryof. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.